Daniel J. George, MD | Authors


The Evolving Treatment Landscape of Prostate Cancer

October 20, 2019

Daniel J. George, MD, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate, and androgen receptor antagonists, like apalutamide and enzalutamide, have changed the landscape.